/* ProTGen site — shared content (beliefs, doorways, milestones, FAQ, team, resources) */

const BELIEFS = [
  { n: "01", short: "A major unsolved problem", title: "Immune compromise is a major, under‑addressed problem.",
    body: "Disease, treatment, and age leave many patients without durable immune protection — a gap modern medicine rarely repairs.",
    meta: "Human + clinical consequence" },
  { n: "02", short: "A distinct frontier", title: "Restoring immune competence is a distinct therapeutic frontier.",
    body: "Not a variation on immune modulation. A different therapeutic job: rebuild the system that must protect the patient afterward.",
    meta: "Category frame" },
  { n: "03", short: "A real leverage point", title: "Targeted Notch activation is a plausible leverage point.",
    body: "An enabling control point for rebuilding adaptive immune function — a once‑undruggable pathway, made targetable.",
    meta: "Enabling biology" },
  { n: "04", short: "Precise & disciplined", title: "ProTGen's platform makes the biology precise, controlled, and useful.",
    body: "Targeted, programmable, and disciplined — engineered for therapeutic control in vivo and ex vivo, not a generic platform claim.",
    meta: "Differentiation" },
  { n: "05", short: "A focused first wedge", title: "ProT‑096 is the right first clinical wedge and proof point.",
    body: "The first disciplined proof of platform logic in a high‑need population — not the whole company, the first evidence.",
    meta: "First proof point" },
  { n: "06", short: "Credible execution", title: "ProTGen understands execution.",
    body: "CMC, manufacturing, IND path, biomarkers, safety, and a milestone sequence that creates value at each step.",
    meta: "Clinical transition" },
  { n: "07", short: "A conversation now", title: "The opportunity deserves a conversation now.",
    body: "Biology, manufacturing, and clinical need are converging. Access is most valuable before the category becomes obvious.",
    meta: "Why now" },
];

const DOORWAYS = [
  { key: "Champion", word: "Portable", h: "The internal champion", need: "Carry the story into an investment committee or BD meeting — and have it survive the handoff.",
    provide: "A portable explanation, one‑pager, proof stack, and objection‑handling language.", cta: "Get the one‑pager" },
  { key: "Clinical", word: "Executable", h: "The clinical‑transition investor", need: "Decide whether ProTGen is moving from scientific promise to an executable clinical program.",
    provide: "ProT‑096 detail, milestone bridge, CMC/manufacturing proof, and risk sequence.", cta: "Request diligence briefing" },
  { key: "Category", word: "Competence", h: "The category‑creation investor", need: "Decide whether ProTGen can define a new therapeutic category.",
    provide: "A large category frame anchored by a focused first wedge — ambition with discipline.", cta: "Request investor briefing" },
  { key: "Partner", word: "Option", h: "The strategic BD partner", need: "Understand where ProTGen fits in a future portfolio before the category becomes obvious.",
    provide: "Platform adjacency, portfolio‑fit logic, and a structured path to option value.", cta: "Contact partnering" },
];

const MILESTONES = [
  { phase: "01 · Biology", status: "on", h: "Targeted Notch activation validated", p: "A proprietary platform that programs cell fate in vivo and ex vivo — establishing a targetable control point in a historically undruggable pathway." },
  { phase: "02 · Program", status: "on", h: "ProT‑096 selected as first wedge", p: "A personalized progenitor T‑cell therapy directed at refractory hematologic malignancies — a high‑need, evaluable first population." },
  { phase: "03 · CMC / IND", status: "next", h: "Manufacturing & IND preparation", p: "Cellares partnership applies automated manufacturing, integrated QC, and regulatory support toward IND submission." },
  { phase: "04 · Clinic", status: "future", h: "First‑in‑human proof", p: "ProT‑096 enters the clinic to generate the first interpretable evidence of immune reconstitution." },
  { phase: "05 · Platform", status: "future", h: "Platform validation & expansion", p: "Clinical proof opens disciplined expansion across oncology, regenerative medicine, and age‑related immune decline." },
];

const FAQS = [
  { obj: "“Interesting, but too early.”", q: "What can actually be diligenced today?", a: "The platform biology and the ProT‑096 program logic are defined now, with a manufacturing and IND path underway through the Cellares partnership. The milestone bridge makes explicit what is de‑risked, what is in progress, and what the next value‑inflection point is — so diligence does not have to wait for first‑in‑human data to begin." },
  { obj: "“This is another cell therapy.”", q: "How is this different from CAR‑T, bispecifics, or other cell therapies?", a: "Most modalities attack disease. ProTGen's job is different: rebuild the adaptive immune system that disease and treatment leave behind. ProT‑096 is a progenitor T‑cell therapy, but the company is organized around a category — restoring immune competence — not a single modality." },
  { obj: "“Powerful but risky pathway.”", q: "Notch is a difficult pathway — why is targeted activation credible?", a: "The platform is built specifically around targeted, controlled activation rather than systemic pathway modulation. Precision and programmability are the point: activate the right signal, at the right place, to rebuild a functional repertoire." },
  { obj: "“Too broad, too early.”", q: "Isn't a platform claim premature for a company at this stage?", a: "Everything is anchored in ProT‑096 as the first proof point. The platform horizon is named as disciplined option value, not a lead claim. One large category, one clear first wedge, one sequence of proof." },
  { obj: "“I need the founder to explain it.”", q: "Can the story travel without Carter in the room?", a: "That is a core design goal of this site and the one‑pager. The belief sequence, proof bridge, and audience doorways are built so an internal champion can retell ProTGen accurately and persuasively in under two minutes — without the founder present." },
];

const TEAM = [
  { name: "Carter Cliff", role: "Founder & Chief Executive Officer", bio: "Leads ProTGen's scientific vision and the strategy to translate targeted Notch activation into a disciplined clinical program.", real: true },
  { name: "[ Chief Scientific Officer ]", role: "Platform & translational biology", bio: "Placeholder — to be confirmed. Oversees Notch activator design, thymic reactivation biology, and the path from mechanism to repertoire.", real: false },
  { name: "[ Chief Medical Officer ]", role: "Clinical development", bio: "Placeholder — to be confirmed. Owns ProT‑096 clinical strategy, patient selection, biomarkers, and safety.", real: false },
  { name: "[ Head of CMC ]", role: "Manufacturing & quality", bio: "Placeholder — to be confirmed. Leads the manufacturing strategy and the Cellares partnership toward IND.", real: false },
  { name: "[ Head of Regulatory ]", role: "Regulatory & IND", bio: "Placeholder — to be confirmed. Directs the IND path and regulatory interactions.", real: false },
  { name: "[ Scientific Advisor ]", role: "Notch & immune development", bio: "Placeholder — to be confirmed. Independent scientific guidance on Notch biology and adaptive immune reconstitution.", real: false },
];

const RESOURCES = [
  { pillar: "Immune competence", title: "What does it mean to restore immune competence?", excerpt: "A plain‑English definition of the category ProTGen is building — and why it is distinct from immune modulation.", meta: "Explainer · 6 min read" },
  { pillar: "Targeted Notch activation", title: "Why Notch matters in adaptive immune development", excerpt: "How a historically undruggable pathway became a targetable control point for rebuilding the repertoire.", meta: "Explainer · 8 min read" },
  { pillar: "Thymic reactivation", title: "The thymus as an immune‑reconstitution control point", excerpt: "Why reactivating foundational immune‑development pathways is the lever for durable protection.", meta: "Explainer · 7 min read" },
  { pillar: "ProT‑096", title: "ProT‑096 as the first proof point for immune competence", excerpt: "How the lead program anchors the platform in a focused, evaluable clinical wedge.", meta: "Program brief · 5 min read" },
  { pillar: "CMC / manufacturing", title: "Why repeatable manufacturing matters for personalized cell therapy", excerpt: "Reproducibility and quality as a precondition for clinical transition — and the Cellares approach.", meta: "Explainer · 6 min read" },
  { pillar: "Partnering", title: "Where immune competence restoration fits a future portfolio", excerpt: "Adjacencies across hematology, cell therapy, immunology, regenerative medicine, and aging biology.", meta: "Partner note · 5 min read" },
];

Object.assign(window, { BELIEFS, DOORWAYS, MILESTONES, FAQS, TEAM, RESOURCES });